References
- Thomas HC, Montano L, Goodall A, De Koning R, Oladapo J, Wiedan KH. Immunological mechanisms in chronic hepatitis B virus infection. Hepatology 1982; 2: 116S–121S
- Mondelli M, Eddleston A LWF. Mechanisms of liver cell injury in acute and chronic hepatitis B. Semin Liver Dis 1984; 4: 47–53
- Chang TW, Weinsen L. Antiviral activity of isoprinosine in vitro and in vivo. Am J Med Sci 1973; 265: 143–146
- Hadden JW, Coll E. Levamisole and inosiplex: antiviral agents with immunopotentiating action. Ann NY Acad Sci 1977; 284: 139–145
- Dabrowska-Bernstein BK, Cianciara J, Loch T, Gabinska E, Stasiak A, Dabrowski M. Isoprinosine—a new immunostimulator and virostatic for the treatment of chronic active hepatitis (CAH-HBsAg+). Abstract. 18th Meeting of the European Association for the Study of the Liver. 1983. SouthamptonEngland
- Kaplan PM, Greenman RL, Gerin JL, Purcell RH, Robinson WS. DNA polymerase associated with human hepatitis B antigen. J Virol 1973; 12: 995–1005
- Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A. Seroconversion from hepatitis Be antigen to anti-Be in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195–199
- Hoofnagle JH, Dusheiko GM, Seeff IB, Jones EA, Waggoner JG, Buskell-Bales Z. Seroconversion from hepatitis Be antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744–748
- Hoofnagle JH. Alpha interferon therapy of chronic viral hepatitis. Hepatol Rapid Lit Rev 1990; 20: 11–15
- Viola LA, Barrisen IG, Coleman JC, Paradinas FJ, Fluker JL, Evans BA, Murray-Lyon IM. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain. Lancet 1981; 2: 1156–1159
- Eddleston A LWF, Williams R. Inadequate antibody response to HBs antigen or suppressor T-cell defect in development of active chronic hepatitis. Lancet 1974; 2: 1543–1548